Skip to main content
SpringerLink
Log in

Serum creatine kinase elevation as a possible complication of therapy with olanzapine

  • Case Report
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Arzneimittelkommission der deutschen Ärzteschaft (2002) Olanzapin: hyperosmolares Coma diabeticum, Rhabdomyolyse, Niereninsuffizienz. Dtsch Ärzteblatt 99(11):741–742

    Google Scholar 

  • Baumgart U, Schmid R, Spiessl H (2005) Olanzapine-induced acute rhabdomyolysis – a case report. Pharmacopsychiatry 38(1):36–37

    Article  PubMed  CAS  Google Scholar 

  • Berry N, Pradhan S, Sagar R, Gupta SK (2003) Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy. 23:255–259

    Article  PubMed  Google Scholar 

  • Filice GA, McDougal BC, Ercan-Fang N, Billington CJ (1998) Neuroliptic malignant syndrome associated with olanzapine. Ann Pharmacother 32:1158–1159

    Article  PubMed  CAS  Google Scholar 

  • Gheorgiu S, Knobler HY, Drumer D (1998) Recurrence of neuroleptic malignant syndrome with olanzapine treatment [letter]. Am J Psychiatry 156:1836

    Google Scholar 

  • Kando JC, Shepski JC, Satterlee W, Patel JK, Reams SG, Green AI (1997) Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. Ann Pharmacother 31:1325–1334

    PubMed  CAS  Google Scholar 

  • Marcus EL, Vass A, Zislin J (1999) Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother 33:697–700

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, Cola PA, Parsa M (1996) Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15:395–405

    Article  PubMed  CAS  Google Scholar 

  • Reeves RR, Torres RA, Liberto V, Hart RH (2002) Atypical neuroleptic malignant syndrome associated with olanzapine. Pharmacotherapy 22:641–644

    Article  PubMed  Google Scholar 

  • Rosebragh CJ, Flockhart DA, Yasuda SU, Woosley RL (2001) Olanzapine-induced rhabdomyolysis. Ann Pharmacother 35(9):1020–1023

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department Psychiatry and Psychotherapy, University Hospital of Freiburg, Hauptsrtasse 5, 79098, Freiburg, Germany

    Evgeniy Perlov, Ludger Tebartz van Elst, Martin Czygan, Emanuel Bubl & Dieter Ebert

Authors
  1. Evgeniy Perlov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludger Tebartz van Elst
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Czygan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emanuel Bubl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dieter Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evgeniy Perlov.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perlov, E., Tebartz van Elst, L., Czygan, M. et al. Serum creatine kinase elevation as a possible complication of therapy with olanzapine. Naunyn Schmied Arch Pharmacol 372, 168–169 (2005). https://doi.org/10.1007/s00210-005-0004-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-005-0004-7

Keywords

Search

Navigation